Redd&Whyte Appoints New Director of Business Development
News Aug 23, 2012
The appointment is one of a series of new hires, amid strategic restructuring within Redd&Whyte.
Rob Harkness brings specialist technical understanding of software and robotics, in addition to an impressive track record in business development.
He joins Redd&Whyte from Process Analysis & Automation, Ltd (PAA), where he worked for 13 years, initially as a software programmer and project manager, before progressing to leading Business Development in 2010.
His PhD (University of Surrey) focused on novel scheduling software for biochemical assays.
Rob made a significant contribution to PAA’s success in becoming a major provider of laboratory automated solutions, and will now lead Redd&Whyte’s global Business Development team.
“This is a crucial time for our company,” said Roger Poole, Managing Director at Redd&Whyte. “We have been making significant changes on a number of levels over the past few months, and Rob’s appointment forms an important part of our new business strategy.”
“It also demonstrates our continued commitment to developing enabling technology for our customers, through our approach of open innovation,” Roger said.
Roger continued, “Our products, including the award-winning Preddator microplate dispenser, are all developed through close collaboration with our customers, to help solve their liquid handling challenges and overcome perceived barriers to research.”
Redd&Whyte is involved in developing a range of novel robotic instruments with the fluid handling capabilities that laboratory scientists need to actually achieve their research visions.
The company’s specialist areas include nano dispensing, high throughput screening and point of care (PoC) testing.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
New Speakers from Roche and Imperial College London Announced for SMi’s ADMET EventNews
SMi Group Reports: With less than 4 weeks left until the 13th annual ADMET Conference commences in London, SMi announces two new speakers joining the event.READ MORE